March 16, 2022
Alnylam Publishes 2021 Corporate Responsibility Report
We're committed to taking bold actions that improve the health of humanity. Our 2021 Corporate Responsibility Report provides details on our progress...
Read More ›
February 28, 2022
Supporting Health Equity for All Through Leadership, Action and Partnership
"Health equity" means that everyone has a fair and just opportunity to live the healthiest life possible, regardless of who they are, where they live or how...
Read More ›
February 4, 2022
Alnylam Receives Prestigious Massachusetts Economic Impact Award
We are pleased and honored to have been named a Gold Team Massachusetts Economic Impact Award winner for 2022 by MassEcon.
Read More ›
January 26, 2022
Alnylam Named to Bloomberg's Gender-Equality Index for 2nd Year in a Row
Alnylam has been named to Bloomberg's 2022 Gender-Equality Index (GEI) - an important diversity, equity and inclusion benchmark, for the 2nd year in a row.
Read More ›
December 21, 2021
Alnylam Publishes 2021 Patient Access Philosophy Report
Alnylam has published its 2021 Patient Access Philosophy Report detailing its actions as a company to provide access to its medicines for those who may...
Read More ›
December 16, 2021
Guest Post: Creating Connections to Support the hATTR Amyloidosis Community
Susanne Berglund is the Chancellor of FAMY Norrbotten, an amyloidosis patient advocacy group reflects on the importance of making connections to support...
Read More ›
December 2, 2021
Alnylam Named #1 Largest Employer in MA for 2021 by The Boston Globe
Alnylam was named to The Boston Globe's Top Places to Work list for the 7th year in a row and the #1 company in the Largest employer category.
Read More ›
October 29, 2021
Alnylam Named a Science Magazine Top Employer for 3rd Year in a Row
Alnylam has been named to Science magazine's 2021 Top Employers list - our third year in a row on the list and ranking in the top 5 companies.
Read More ›
October 28, 2021
Alnylam Names Dr. Yvonne Greenstreet New CEO
Dr. Yvonne Greenstreet, currently Alnylam's President and COO, has been named Alnylam's new CEO effective year-end 2021, taking over from Dr. John Maraganore.
Read More ›
October 13, 2021
Alnylam Challengers - a Health Equity Community Impact Program
Alnylam Challengers is Alnylam's signature CSR Community Impact Program. It aims to improve health access to underserved communities.
Read More ›
The following content may not be associated with Alnylam Pharmaceuticals.
Links to all outside sites are provided as a reference for our visitors.
Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.
Proceed to Site